The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 16, 2024

Filed:

Mar. 28, 2022
Applicant:

Molecular Templates, Inc., Austin, TX (US);

Inventors:

Eric Poma, New York, NY (US);

Erin Willert, Round Rock, TX (US);

Assignee:

Molecular Templates, Inc., Austin, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/25 (2006.01); A61K 39/00 (2006.01); C07K 14/245 (2006.01); C07K 16/00 (2006.01); C07K 16/08 (2006.01); C07K 16/10 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C12N 9/10 (2006.01); C12N 9/24 (2006.01); C12N 15/62 (2006.01);
U.S. Cl.
CPC ...
C07K 14/25 (2013.01); C07K 14/245 (2013.01); C07K 16/00 (2013.01); C07K 16/085 (2013.01); C07K 16/088 (2013.01); C07K 16/1063 (2013.01); C07K 16/286 (2013.01); C07K 16/2863 (2013.01); C07K 16/2866 (2013.01); C07K 16/2887 (2013.01); C07K 16/32 (2013.01); C12N 9/1077 (2013.01); C12N 9/2497 (2013.01); C12N 15/62 (2013.01); C12Y 204/02036 (2013.01); C12Y 302/02022 (2013.01); A61K 2039/6037 (2013.01); C07K 2319/04 (2013.01); C07K 2319/33 (2013.01); C07K 2319/40 (2013.01); C07K 2319/55 (2013.01); Y02A 50/30 (2018.01);
Abstract

The present invention is directed to T-cell epitope delivering polypeptides which deliver one or more CD8+ T-cell epitopes to the MHC class I presentation pathway of a cell, including toxin-derived polypeptides which comprise embedded T-cell epitopes and are de-immunized. The present invention provides cell-targeted, CD8+ T-cell epitope delivering molecules for the targeted delivery of cytotoxicity to certain cells, e.g., infected or malignant cells, for the targeted killing of specific cell types, and the treatment of a variety of diseases, disorders, and conditions, including cancers, immune disorders, and microbial infections. The present invention also provides methods of generating polypeptides capable of delivering one or more heterologous T-cell epitopes to the MHC class I presentation pathway, including polypeptides which are 1) B-cell and/or CD4+ T-cell de-immunized, 2) comprise embedded T-cell epitopes, and/or 3) comprises toxin effectors which retain toxin functions.


Find Patent Forward Citations

Loading…